NeurologyLive® Friday 5 — November 29, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Assessing Omaveloxolone’s Positive Long-Term Safety Profile: David Lynch, MD, PhD

The professor of neurology at the University of Pennsylvania Perelman School of Medicine provided clinical insight on a long-term safety analysis of omaveloxlone, the first FDA-approved treatment for Freidreich ataxia. [WATCH TIME: 4 minutes]

2: Overviewing Major Changes to the 2024 Restless Legs Syndrome Guidelines: Andy Berkowski, MD, PhD

The vice chair of the American Academy of Sleep Medicine’s Clinical Practice Guidelines Task Force provided in-depth insight on the most noted changes to the 2024 RLS guidelines clinicians should be aware of. [WATCH TIME: 9 minutes]

3: Hiding in Plain Sight: MS and Domestic Violence and Abuse

When looking at the intersection of MS and domestic abuse, one can find hidden challenges and a need for innovative efforts to support vulnerable patients and survivors.

4: NeuroVoices: Rebecca M. Edelmayer, PhD, on Advancing Blood Biomarkers in Alzheimer Disease for Earlier Diagnosis and Treatment Intervention

In our latest Q&A for NeuroVoices, the vice president of scientific engagement at the Alzheimer's Association discussed advancements in blood biomarker tests, their use in specialty care, and the development of clinical guidelines for broader integration.

5: Shared Decision-making for Selection of FDA-approved Therapies for NMOSD

A panelist discusses how when treating NMOSD, neurologists should consider the patient's clinical characteristics, safety profiles, administration requirements, and cost-effectiveness when selecting between FDA-approved therapies such as eculizumab, inebilizumab, satralizumab, ravulizumab, and rituximab.